Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial
Titel:
Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial
Auteur:
Guarneri, V. Cinieri, S. Orlando, L. Bengala, C. Mariani, G. Bisagni, G. Frassoldati, A. Zamagni, C. De Salvo, G. Conte, P.F.